ArticleMolecular biology reports2025
Combined effects of 5-azacytidine and oleuropein on miR-149-3p, miR-375, miR-574-5p expression and apoptosis in acute myeloid leukemia (AML) cell lines HL-60 and THP-1.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAcute myeloid leukemia (AML) is an aggressive hematological malignancy characterized by the rapid proliferation of immature myeloid cells and poor clinical outcomes. Despite conventional treatments such as chemotherapy and hematopoietic stem cell transplantation, relapse and resistance remain major challenges. Epigenetic alterations-particularly dysregulated DNA methylation and microRNA (miRNA) expression- are crucial in AML pathogenesis.
objectiveThis study aimed to investigate the synergistic effects of azacitidine, a DNA methyltransferase inhibitor, and oleuropein, a natural polyphenol with anticancer properties, on AML cell lines (THP-1 and HL-60).
methodsAML cells were treated with azacitidine, oleuropein, or their combination. Cell proliferation was evaluated using MTT assays, apoptosis was assessed via flow cytometry (Annexin V-FITC/PI staining), and miRNA expression levels were quantified using real-time PCR.
resultsBoth azacitidine and oleuropein reduced cell viability and induced apoptosis in a dose- and time-dependent manner. The combination treatment significantly enhanced apoptosis, resulting in a 2.5-fold increase in Annexin V-positive HL-60 cells at 72 h. Additionally, the treatment modulated miRNA expression, upregulating miR-149-3p and miR-375, while downregulating miR-574-5p.
conclusionThe synergistic effects of oleuropein and azacitidine suggest a promising therapeutic strategy for AML by targeting epigenetic mechanisms and miRNA pathways. Further in vivo studies and clinical trials are warranted to validate these findings and optimize treatment protocols.
Indexed as
Identifiers
41105301What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.